Nelson has been critical of the $80 billion agreement. In fact, he called for a larger share of savings from the pharmaceutical manufacturers during a Senate Finance Committee hearing in September.
In an amendment, he proposed that the pharmaceutical industry "surrender a financial windfall" it gets on drugs sold to Medicare patients who also qualify for Medicaid, called "dual eligibles." The amendment, which Nelson said would saved taxpayers an estimated $106 billion over 10 years, was based on estimates provided by the Congressional Budget Office. It was defeated in a 13-10 vote at that time.